Our GalNAc-oligonucleotide conjugation services support biotechnology companies, pharmaceutical research teams, oligonucleotide developers, CROs, and academic laboratories that require hepatocyte-directed oligonucleotide constructs for discovery and development studies. N-acetylgalactosamine (GalNAc) can engage the asialoglycoprotein receptor (ASGPR) on hepatocytes, providing a defined ligand-based approach for studying receptor-mediated uptake of siRNA, antisense oligonucleotides, and other modified nucleic acid formats.
We coordinate oligonucleotide sequence requirements, GalNAc valency, attachment position, linker architecture, conjugation route, purification, and analytical characterization within one project plan. This integrated approach helps customers select a chemically practical construct, control conjugate-related impurities, and obtain materials suited to uptake, target-modulation, structure–activity, and delivery-mechanism studies. Related technical background is available in our overview of GalNAc delivery technology.
Ligand Architecture Selection: A GalNAc construct cannot be selected only by choosing a sugar label. Monovalent, multivalent, clustered, and distributed ligand formats differ in synthetic complexity, spatial presentation, linker requirements, and receptor-engagement behavior. We evaluate the intended oligonucleotide modality and experimental objective before recommending a ligand architecture.
Attachment Site Compatibility: Placement at the 3' terminus, 5' terminus, an internal position, or a selected siRNA strand can affect synthesis strategy and downstream oligonucleotide function. For duplex siRNA, GalNAc is commonly positioned on the sense or passenger strand, but strand design, terminal modifications, and duplex requirements must be reviewed together to avoid disrupting the intended construct.
Linker and Handle Design: Spacer length, hydrophilicity, branching, cleavability, and reactive-handle placement can influence coupling efficiency, ligand accessibility, chromatographic behavior, and final material handling. We select linkers and functional handles that are compatible with the GalNAc ligand, oligonucleotide modifications, purification method, and planned research workflow.
Modified Oligonucleotide Compatibility: Phosphorothioate backbones, 2'-modified sugars, terminal caps, fluorescent reporters, and other modifications may introduce deprotection, coupling, solubility, or purification constraints. Our planning process reviews the complete construct rather than treating GalNAc attachment as an isolated labeling step.
Purification and Analytical Resolution: GalNAc conjugation changes molecular mass, polarity, and chromatographic retention. Incomplete coupling, unconjugated oligonucleotide, ligand-related species, and truncated sequences may require method-specific separation. Our broader oligonucleotide conjugation capabilities integrate purification and analytical planning with the selected chemistry.
Our service platform covers early construct planning through synthesis, conjugation, purification, analytical verification, duplex preparation, and technical handoff. Projects may begin with a customer-defined sequence and ligand, a preliminary construct concept, or a request for comparative GalNAc designs.
Service scope is adjusted to the oligonucleotide modality, modification pattern, attachment site, ligand architecture, material quantity, and downstream research use. Customer-supplied oligonucleotides or GalNAc reagents can also be evaluated when their identity, functionality, and compatibility are adequately defined.
GalNAc conjugate design should be selected according to receptor-engagement studies, oligonucleotide modality, manufacturing route, and the type of comparison the customer intends to perform. The table below summarizes common construct options and their principal decision factors.
| Construct Option | Typical Placement | Compatible Routes | Best-Suited Research Use | Key Decision Factors |
| Monovalent GalNAc | 3', 5', internal, or selected strand position | Phosphoramidite incorporation, functionalized support, or post-synthetic coupling | Ligand-position studies, scaffold screening, and structure–activity comparisons | Ligand accessibility, number of GalNAc units, spacer length, and receptor-binding study design |
| Bivalent GalNAc | Terminal or branched linker placement | Branched building block, modular assembly, or solution-phase coupling | Valency optimization and comparison with mono- or trivalent constructs | Branching geometry, linker symmetry, synthetic accessibility, and purification resolution |
| Triantennary GalNAc | Commonly 3' or 5'; strand-specific placement for duplex formats | GalNAc-functionalized support, cluster phosphoramidite, or post-synthetic conjugation | Multivalent ASGPR-engagement and hepatocyte-uptake research | Cluster architecture, attachment orientation, deprotection compatibility, and conjugate purity |
| Distributed GalNAc | Multiple sequential or separated positions | Stepwise solid-phase incorporation or modular linker assembly | Ligand-spacing and alternative multivalent presentation studies | Position-specific coupling efficiency, total ligand loading, sequence context, and analytical complexity |
| GalNAc-siRNA Duplex | Commonly on the sense or passenger strand | Conjugate synthesis followed by strand purification and duplex annealing | RNA interference, receptor-mediated uptake, and hepatocyte target-modulation studies | Strand selection, guide-strand preservation, duplex ratio, annealing behavior, and modification pattern |
| GalNAc-ASO Construct | Usually terminal, with project-specific alternatives | Integrated synthesis or post-synthetic coupling | Single-stranded target-modulation, uptake, and linker-comparison studies | Backbone chemistry, terminal modifications, conjugation stability, solubility, and chromatographic behavior |
| Dual-Functional Conjugate | GalNAc at one site with a reporter or secondary function at another | Orthogonal solid-phase and solution-phase chemistry | Uptake tracking, localization studies, binding assays, and mechanism research | Orthogonal handles, reporter interference, overall hydrophobicity, purification burden, and analytical confirmation |
No single analytical method fully describes a GalNAc-oligonucleotide conjugate. A fit-for-purpose analytical plan combines identity, purity, content, conjugation, and format-specific assessments so that customers can understand what material was produced and whether it is suitable for the intended experiment.
| Analytical Category | Primary Objective | Typical Method Options | Common Issues Assessed | Project Value |
| Identity Confirmation | Confirm the expected intact molecular composition | LC-MS, high-resolution MS, or MALDI-TOF | Incorrect mass, incomplete modification, ligand loss, or unexpected adducts | Verifies that the intended sequence and GalNAc construct were obtained |
| Purity Profiling | Resolve the principal product from oligonucleotide- and conjugation-related impurities | RP-HPLC, UPLC, ion-exchange HPLC, or orthogonal chromatography | Unconjugated oligo, truncated sequences, over-modified species, and residual ligand-related peaks | Supports material selection and interpretation of downstream study results |
| Conjugation Assessment | Evaluate whether GalNAc attachment proceeded at the intended site and extent | Comparative chromatography, mass analysis, and reaction-profile review | Incomplete coupling, handle hydrolysis, multiple attachment, or linker degradation | Identifies route-specific problems before material is advanced |
| Content and Concentration | Estimate usable oligonucleotide content or solution concentration | UV absorbance and project-specific content calculations | Salt contribution, moisture, extinction-coefficient assumptions, and concentration variability | Helps customers prepare reproducible dosing and assay solutions |
| Duplex Assessment | Confirm strand combination and evaluate duplex-related behavior | Native chromatography, capillary electrophoresis, PAGE, or thermal analysis where appropriate | Free strands, incorrect strand ratio, incomplete annealing, or unexpected duplex species | Provides greater confidence in GalNAc-siRNA materials used for comparative studies |
| Solubility Review | Assess handling behavior in the proposed buffer or concentration range | Visual assessment, concentration recovery, and buffer-compatibility testing | Precipitation, adsorption, aggregation, or poor redissolution after drying | Reduces avoidable handling problems during downstream experiments |
| Stability Assessment | Examine conjugate integrity under selected storage or use conditions | Time-point chromatography, mass confirmation, and appearance monitoring | Linker cleavage, ligand loss, oligonucleotide degradation, or concentration-dependent changes | Supports storage-condition selection and experimental planning |
Each project follows a chemistry-led workflow that connects construct design with practical synthesis, purification, and analytical requirements. Activities are adjusted for customer-supplied materials, integrated oligonucleotide synthesis, comparative construct panels, or duplex siRNA preparation.
We collect the oligonucleotide sequence, modality, strand arrangement, modification map, preferred GalNAc architecture, attachment site, quantity, purity expectation, formulation preference, and planned research use. A preliminary construct map is created so that all components and deliverables are clearly defined.
The team evaluates whether solid-phase incorporation, functionalized support, post-synthetic coupling, or a hybrid route is most suitable. Linker chemistry, handle orthogonality, deprotection tolerance, expected impurity profile, and purification feasibility are reviewed before the proposal is finalized.
Oligonucleotide strands and GalNAc-containing building blocks are prepared or qualified according to the selected route. Functional handles, protecting groups, terminal modifications, and any secondary labels are checked to confirm that they are compatible with the planned conjugation sequence.
GalNAc is incorporated during synthesis or coupled after oligonucleotide preparation. Reaction progress is monitored, and the conjugate is purified using a method selected for its charge, hydrophobicity, ligand architecture, and impurity profile. Conditions may be refined when standard separation does not provide adequate resolution.
Identity, purity, content, and other agreed attributes are evaluated. For siRNA projects, purified strands can be annealed under controlled conditions and assessed for duplex formation. Results are reviewed before final processing so that any chemistry- or format-related concerns can be addressed.
Materials are supplied in the agreed dried or solution format together with sequence information, construct description, analytical results, handling guidance, and project-specific documentation. Post-delivery support is available for reconstitution, study controls, follow-on designs, and comparative conjugate planning.
GalNAc conjugation projects require coordination between oligonucleotide chemistry, carbohydrate-ligand design, linker selection, purification, and analytical science. Our platform is structured to reduce technical gaps between these activities and provide customers with a clearly defined, experimentally usable construct.
GalNAc-oligonucleotide conjugates are used in research programs that investigate receptor-mediated uptake, hepatocyte-directed delivery, oligonucleotide target modulation, and ligand–linker structure relationships. Our services support both individual constructs and comparative panels designed to answer specific development questions.
Whether your project requires a triantennary GalNAc-siRNA duplex, a GalNAc-ASO construct, a custom linker, a comparative ligand panel, or conjugation of customer-supplied material, our team can help define a practical chemistry and analytical plan. Provide the sequence, oligonucleotide format, modification map, preferred attachment position, desired material quantity, and planned research use so that feasibility, route options, and deliverables can be reviewed efficiently. Related options include GalNAc labeling of oligonucleotides, diamine-scaffold GalNAc-siRNA conjugates, and oligonucleotide stability testing. Contact us to request a technical assessment and project proposal.
GalNAc-oligonucleotide conjugation involves attaching N-acetylgalactosamine (GalNAc) to oligonucleotides, enhancing their stability and targeting ability, especially for liver delivery. This method improves drug distribution and efficacy, particularly for liver-specific diseases.
GalNAc acts as a high-affinity ligand that binds to the GalNAc receptors on hepatocytes, facilitating targeted delivery to liver cells. This targeted mechanism significantly improves the efficiency of treatments aimed at liver-related diseases.
GalNAc-oligonucleotide conjugation enhances the stability, bioavailability, and specificity of oligonucleotides, particularly for liver-targeted therapies. It improves drug delivery efficiency and reduces off-target effects.
Loading ......
